Press release
Aplastic Anemia Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight
Unlock key insights into the Aplastic Anemia Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Aplastic Anemia Therapeutics Market Outlook [https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Aplastic Anemia Market Report
* In April 2025, Fred Hutchinson Cancer Center announced a phase II trial tests how well a ruxolitinib-based graft versus host disease (GVHD) prevention (prophylaxis) regimen works before, during, and after bone marrow/stem cell transplantation (hematopoietic cell transplantation [HCT]) in patients with acquired aplastic anemia.
* In March 2025, Novartis Pharmaceuticals announced a phase II study to characterize the pharmacokinetics (PK) after oral administration of eltrombopag in combination with immunosuppressive therapy in pediatric patients with previously untreated or relapsed/refractory severe aplastic anemia or recurrent aplastic anemia.
* The total Aplastic Anemia Treatment Market Size was found to be ~USD 270 million in 2023 in the 7MM, which is further expected to increase by 2034.
* Among the 7MM, Japan accounts for the second highest total aplastic anemia drugs market. The Aplastic Anemia Treatment Market Size in Japan has been assessed to be ~USD 35 million in 2023, expected to increase during the forcast period.
* During the forecast period, Aplastic Anemia pipeline candidates such as Omidubicel-onlv, REGN7257, and ALVAIZ (eltrombopag choline) are expected to drive the rise in Aplastic anemia market size.
* Among EU4 and the UK, Germany accounts for the highest Aplastic Anemia Treatment Market Size with ~USD 14 million in 2023, followed by France.
* Aplastic Anemia Treatment Market Size is expected to increase due to several factors such as an increase in disease incidence in Asian countries, high patient uptake of PROMACTA (until expected patent expiry in 2025), approval of Teva Pharma's ALVAIZ in the US, and Kyowa Kirin's ROMIPLATE in Japan along with the expected launch of potential emerging therapies.
* The leading Aplastic Anemia Companies such as Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, and others.
* Promising Aplastic Anemia Pipeline Therapies such as Romiplostim, Eltrombopag, PF-06462700, AMG531, Rabbit ATG, Cyclosporine and others.
Stay ahead in the competitive landscape of the Aplastic Anemia Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Aplastic Anemia Treatment Market Size [https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Aplastic Anemia Epidemiology Segmentation in the 7MM
* Aplastic Anemia Incident Cases
* Aplastic Anemia Severity-Specific Cases
* Aplastic Anemia Age-specific Cases
Download the report to understand which factors are driving Aplastic Anemia epidemiology trends @ Aplastic Anemia Prevalence [https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Aplastic Anemia Marketed Therapies
* ALVAIZ (eltrombopag choline): Teva Pharmaceuticals
ALVAIZ (eltrombopag choline) is an oral thrombopoietin (TPO) receptor agonist that works to increase platelet production by interacting with the transmembrane domain of the human TPO-receptor to initiate signaling cascades that induce proliferation and differentiation of megakaryocytes. Lowest dose of ALVAIZ is use to achieve and maintain a hematologic response. Dose adjustments are based upon the platelet count. Hematologic response requires dose titration, generally up to 108 mg, and may take up to 16 weeks after starting ALVAIZ.
* ROMIPLATE (romiplostim; AMG531): Kyowa Kirin/Amgen
ROMIPLATE is composed of recombinant protein acting on the thrombopoietin receptor, which has been licensed from Amgen (K-A) to Kyowa Kirin. It was launched as a drug for idiopathic thrombocytopenic purpura (ITP) in April 2011 and for aplastic anemia in patients who had an inadequate response to conventional therapy in June 2019 in Japan. The drug is composed of recombinant protein stimulating hematopoiesis via acting on the thrombopoietin receptors; Acts directly on megakaryocytic progenitor cells and exerts platelet hematopoietic effects. In addition, this drug promotes the proliferation and differentiation of megakaryocytic progenitor cells by binding to and activating thrombopoietin receptors.
Aplastic Anemia Emerging Therapies
* REGN7257: Regeneron Pharmaceuticals
It's a gc cytokine receptor antibody that targets the common g chain (gc; IL-2RG) found in interleukin (IL) receptors for various gc cytokines, including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. It was developed to investigate the potential of targeting gc cytokines for the prevention and treatment of T-cell-mediated diseases. By blocking the signaling of GC cytokines, REGN7257 aims to ameliorate T-cell-mediated pathogenesis. This antibody offers a promising approach to understand better the role of gc cytokines in inflammatory and autoimmune disease settings, where the lack of appropriate neutralizing antibodies recognizing IL-2RG has been a challenge.
* OMISIRGE (omidubicel): Gamida Cell
OMISIRGE is a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood. It is indicated for use in adults and pediatric patients aged 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning. The therapy aims to reduce the time to neutrophil recovery and the incidence of infection in this patient population. Omisirge has received approval for use in hematological malignancies and is currently undergoing evaluation in an ongoing investigator-sponsored Phase I/II study focusing on patients with severe aplastic anemia.
To learn more about Aplastic Anemia Treatment guidelines, visit @ Aplastic Anemia Market Drivers and Barriers [https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Aplastic Anemia Market Outlook
The Aplastic Anemia Prognosis, varies based on the severity of the condition. Some cases can be successfully treated, while others may progress to severe complications, such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Historically, the primary modalities for treating aplastic anemia have been IST and BMT in eligible patients. For individuals with SAA/VSAA deemed suitable for transplant-based interventions, age emerges as a pivotal determinant influencing survival post-matched sibling donor (MSD) allogeneic transplantation. Notably, older patients, often having undergone prior IST, presenting with additional comorbidities, diminished performance status, and an extended duration between diagnosis and BMT, exhibit distinctive challenges in outcomes, with fludarabine-containing regimens offering more promising results in this demographic, albeit based on limited retrospective analyses.
Aplastic Anemia Treatment Market
Aplastic anemia is a rare and severe nonmalignant disease characterized by autoimmune destruction of early hematopoietic cells. Aplastic anemia can be categorized into congenital and acquired forms. Inherited forms are rare and include Fanconi Anemia, Congenital Keratosis, Congenital Pure Red Cell Aplasia, and Shwachman-Diamond Syndrome. Most cases of acquired aplastic anemia occur unrelated to any identifiable causes or for unknown reasons. Researchers believe that most are due to the immune system mistakenly targeting the bone marrow. Specific symptoms vary from case to case. Some individuals may have mild symptoms that remain stable for many years; others may have serious symptoms that can progress to life-threatening complications.
Explore the dynamics of the Aplastic Anemia Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Aplastic Anemia Ongoing Clinical Trials Analysis [https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Aplastic Anemia Market Report
* Coverage- 7MM
* Study Period- 2020-2034
* Aplastic Anemia Companies- Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals , and others.
* Aplastic Anemia Pipeline Therapies- Romiplostim, Eltrombopag, PF-06462700, AMG531, Rabbit ATG, Cyclosporine, and others.
* Aplastic Anemia Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Aplastic Anemia Unmet Needs, KOL's views, Analyst's views, Aplastic Anemia Market Access and Reimbursement
Table of Contents
1. Key Insights
2. Aplastic Anemia Market Report Introduction
3. Executive Summary of Aplastic Anemia
4. Aplastic Anemia Market Overview at a Glance
5 Key Events
6 Aplastic Anemia Epidemiology and Market Forecast Methodology
7 Aplastic Anemia Disease Background and Overview
8 Aplastic Anemia Treatment and Management of Aplastic Anemia
9 Aplastic Anemia Epidemiology and Patient Population
10 Aplastic Anemia Patient Journey
11 Aplastic Anemia Marketed Therapies
12 Aplastic Anemia Emerging Drugs
13 Aplastic Anemia: Market Analysis
14 Aplastic Anemia Unmet Needs
15 Aplastic Anemia SWOT Analysis
16 Aplastic Anemia KOL Views
17 Aplastic Anemia Market Access and Reimbursement
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=aplastic-anemia-treatment-market-size-in-7mm-is-expected-to-grow-at-a-decent-cagr-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/aplastic-anemia-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Aplastic Anemia Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight here
News-ID: 3993465 • Views: …
More Releases from ABNewswire
Best Option Restoration Strengthens South Charlotte Commitment with Local Hiring …
The demand for professional water damage cleanup South Charlotte has seen a consistent increase, driven by factors ranging from seasonal storms to aging infrastructure. This local hiring initiative allows Best Option Restoration of South Charlotte to meet this growing need more effectively. New team members, who are familiar with the specific neighborhoods and common architectural styles of the South Charlotte area, can be dispatched more rapidly.
In a significant move that…
Beyond the Flood: Best Option Restoration Brings Integrated Mold Remediation to …
For homeowners in the region searching for water damage repair near me, the integration of mold remediation is a significant benefit. It means that the company responsible for the initial drying is also accountable for preventing its most common and dangerous consequence. This seamless integration eliminates the need for a homeowner to coordinate with a separate mold mitigation company, ensuring a continuous and comprehensive recovery process.
In the critical aftermath of…
Best Option Restoration Expands Service Area to Offer 24/7 Water Damage Restorat …
The core offering now available to the Fort Mill community is a comprehensive water damage restoration service. This is a multi-stage process that begins the moment a call is placed. Certified technicians arrive promptly to conduct a thorough assessment using advanced moisture detection equipment. This initial step is crucial for identifying the full extent of the damage, including moisture hidden behind walls or under flooring.
In a strategic move to serve…
Is Couples Therapy Right? Signs It's Time to See a Counsellor in Birmingham
Relationships can be both fulfilling and challenging. No matter how strong a couple may seem on the outside, it's natural to face hurdles along the way. Miscommunication, stress, life changes, or unresolved issues can create distance between partners. While every couple goes through ups and downs, knowing when to seek professional support can make all the difference. If you've ever found yourself searching for "couples therapy near me" or wondering…
More Releases for Aplastic
Strategic Partnerships Drive Advancements In Aplastic Anemia Treatment And Resea …
How Are the key drivers contributing to the expansion of the aplastic anemia market?
The escalating expenses on healthcare are anticipated to stimulate the aplastic anemia market's expansion in the future. This growth in healthcare spending is mainly attributed to factors like aging populations and rising chronic illnesses that necessitate expensive treatments. Investments in healthcare facilitate treatments for aplastic anemia by providing funds for specialized medical institutions, innovative therapies, and research…
Leading Element Driving Change in the Aplastic Anemia Market in 2025: Impact Of …
What Is the Estimated Market Size and Growth Rate for the Aplastic Anemia Market?
The market size of aplastic anemia has seen considerable growth in past years. There is expected growth from $6.63 billion in 2024 to $7.03 billion in 2025, with a compound annual growth rate (CAGR) of 6.2%. The historic growth of this market can be credited to several factors, including a rise in the incidence of blood disorders,…
Aplastic Anemia Market: A Growing Need for Treatment
The aplastic anemia market has witnessed significant growth in recent years, driven by advancements in medical technology, increasing awareness of the condition, and the desire for effective treatment options. This post will delve into the market, exploring its size, share, opportunities, challenges, demand, and trends.
Market Size and Share
The aplastic anemia market is a substantial segment of the global hematology and oncology industry. While precise figures can vary depending on data…
Aplastic Anemia Market Size, Share, Industry, Forecast and outlook (2024-2031)
A new Report by DataM Intelligence, titled "Aplastic Anemia Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031,"" offers a comprehensive analysis of the industry, which comprises insights on the Aplastic Anemia market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
This report has a complete table of contents, figures, tables, and charts, as well as insightful analysis. The Aplastic Anemia market has…
Aplastic Anemia Treatment Market - Shaping the Future of Aplastic Anemia Health: …
Newark, New Castle, USA: The "Aplastic Anemia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Aplastic Anemia Treatment Market: https://www.growthplusreports.com/report/aplastic-anemia-treatment-market/8435
This latest report researches the industry structure,…
Global Acquired Aplastic Anemia Market Insights, Forecast
Acquired aplastic anemia is a rare, serious blood disorder, due to failure of the bone marrow failure to produce blood cells. Bone marrow is the spongy substance found in the center of the bones of the body, in adults mainly the spine, pelvis, and large bones of the legs. The global Acquired Aplastic Anemia market is valued at xx million US$ in 2018 and will reach xx million US$ by…
